Sun Pharma to introduce its version of Vortioxetine in India under an exclusive patent license from Lundbeck

Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, Sun Pharma" and includes its subsidiaries and/or associate companies) today announced that one of its wholly-owned subsidiaries has entered into an exclusive patent licensing agreement with H. Lundbeck A/S ("Lundbeck") to market and distribute its own version of Vortioxetine in India under the brand name, VORTIDIF™. The territory of the licensing agreement will only cover India.

Vortioxetine is a novel antidepressant with multimodal activity, which is approved to treat Major Depressive Disorder (MDD) in adults. The product is approved in over 80 countries, including the US, EU, Canada and Australia.

Kirti Ganorkar, CEO of India Business, Sun Pharma, said, "Sun Pharma is the leader in the neuro-psychiatry therapy in India and we always endeavour to bring innovative medicines that fill a need gap. MDD is a serious and complicated disorder and VORTIDIF™ will serve as an important novel treatment option for patients in India."

MDD is one of the leading cause of disability, affecting approximately 246 million people globally and 35 million people in India. MDD is characterised by pronounced changes in mood coupled with distinct psychological and vegetative changes, including sleep, appetite disturbance, subjective fatigue, loss of motivation and drive, ruminative feelings of guilt and despair, problems maintaining mental focus, and suicidal thinking and behaviour.

Sun Pharma is ranked No. 1 by prescriptions and value amongst Neurologists & Psychiatrists in India (IMS MAT Jan 2022). With a strong product portfolio, Sun Pharma's CNS division constantly strives to provide innovative solutions to patients and health care providers in India.

Shares of Sun Pharmaceutical Industries Limited was last trading in BSE at Rs. 919.50 as compared to the previous close of Rs. 904.85. The total number of shares traded during the day was 170894 in over 2444 trades.

The stock hit an intraday high of Rs. 921.75 and intraday low of 903.20. The net turnover during the day was Rs. 155706787.00.

Source : Equity Bulls

Keywords

SunPharmaceuticalIndustries INE044A01036 PatentLicensingAgreement Lundbeck VORTIDIF